Figure 3 | Scientific Reports

Figure 3

From: A Phase 3, randomized, non-inferiority study of a heterologous booster dose of SARS CoV-2 recombinant spike protein vaccine in adults

Figure 3

Summary of Neutralizing Antibodies (nAb) against Omicron B.1.1.529 at each visit (Per protocol population). GMT: Geometric Mean Titer. For each study vaccine, the GMT of Neutralizing Antibodies (nAb) and 95% CI were calculated by transforming to the original scale of log10-transformed mean and its two-sided 95% CI limits at each visit.

Back to article page